Thus, even when the use of aromatase inhibitors deprives a patient of estradiol, prolactin would still be capable of reducing expression of p21 and promoting tumor progression, although prolactin expression would also usually be reduced with aromatase inhibitors [78, 79]. Here, CYP19A1 is linked to neoplasm.